Key Advances in the Treatment of the Critically III: Part II

Dear Colleagues,

Intensive Care Medicine (ICM) aims to address organ-system failures in the context of an extremely broad variety of acute and severe disease states and coexisting comorbid conditions. Accordingly, survival without severe disability may vary from <10% to >90%. Despite intense randomized controlled clinical research for several decades, only a handful of key therapeutic interventions have been shown to directly improve important and/or critical patient outcomes. Examples include lung-protective mechanical ventilation and prone positioning in acute respiratory distress syndrome (ARDS), targeted temperature management, amiodarone, and the vasopressin–steroids–epinephrine combination in cardiac arrest, tranexamic acid in trauma (including head injury), and early antibiotics in sepsis/septic shock. Furthermore, the use of bundles of physiologically and pharmacologically sound interventions, such as those recommended in the context of guidelines for sepsis/septic shock, ARDS and postcardiac arrest care, may have also contributed to the observed improvements in outcomes over the past decades.

The severe acute respiratory syndrome coronavirus-2 pandemic has prompted urgent and intensified research on the development of effective treatments such as the messenger RNA-based vaccines, immunomodulating interventions and antiviral pills. Additionally, extracorporeal membrane oxygenation still constitutes a potentially promising intervention for selected patients with treatment-refractory respiratory and/or circulatory failure. Notably, the rapid evolution of evidence-based ethical guidelines and the introduction of palliative care options seem to increasingly augment the consistency between actually administered treatments and patient/family values, goals and preferences.

This Special Issue invites submissions of reviews and original articles related to any of the aforementioned topics related to ICM.

Prof. Dr. Spyros D. Mentzelopoulos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• respiration
• artificial
• prone position
• respiratory distress syndrome
• respiratory insufficiency
• heart arrest
• hypothermia
• induced
• amiodarone
• vasopressins
• steroids
• epinephrine
• multiple trauma
• wounds and injuries
• tranexamic acid
• sepsis
• anti-bacterial agents
• COVID-19
• COVID-19 vaccines
• COVID-19 breakthrough infections
• COVID-19 drug treatment
• extracorporeal membrane oxygenation

• Key Advances in the Treatment of the Critically Ill in Journal of Clinical Medicine (19 articles)